Bacteriophage Therapy in Implant-Related Orthopedic Infections

Abstract
Bioflm producers pose a major challenge in treating implant-related orthopedic infections (IROIs). The incidence of IROIs
for the closed fracture amounts to 1% to 2% whereas for open fracture it is up to 30%. Due to inappropriate and irrational
use of antibiotics in the management of infections, there is an emergence of a global “antimicrobial resistance crisis”. To
combat these antimicrobial resistance crises, a few innovative and targeted therapies like nanomedicine, phage therapy,
antimicrobial peptides, and sonic therapies have been introduced. In this review, we have detailed the basic mechanisms involved in the employment of bacteriophage therapy for IROIs, along with the preclinical and clinical data on its utility. We also present the guidelines on its regulation, processing, and limitations of bacteriophage therpay to combat the upcoming era of antibiotic resistance.